NKTRNektar Therapeutics
$41.14-25% 1Y
$41.14
$35.1252 weeks$100.35
The financials
Nektar Therapeutics by the numbers
Nektar Therapeutics (NKTR) reported revenue of $10M in Q2 2026 (quarter ended Jun 30, 2026), down 9.3% from the same quarter a year earlier. That came with net loss of $41M. For the full year FY2025, revenue was $55M (−44% year on year) and net income −$164M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was Non Cash Royalty Revenue Related To Sale Of Future Royalties at $11M, 97% of the disclosed total, well ahead of License Collaboration And Other at 2.5%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $10M | $11M | −9.3% |
| Gross profit | n/a | $11M | n/a |
| Operating income | −$42M | −$36M | n/a |
| Net income | −$41M | −$42M | n/a |
| Diluted EPS | −$1.23 | −$2.95 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | $11M | 97% |
| License Collaboration And Other | $300K | 2.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $10.1M (-6.7%)
Non Cash Royalty Revenue Related To Sale Of Future Royalties grew -9.3% year on year
Segment Latestquarter on quarteryear on year
- Non Cash Royalty Revenue Related To Sale Of Future Royalties$10.1M$10.1Mquarter on quarter -6.7%year on year -9.3%-6.7%-9.3%
On our screens:Most shorted stocks